DexCom, Inc.
DexCom, Inc. (DXCM) Stock Competitors & Peer Comparison
See (DXCM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXCM | $76.40 | +0.00% | 30.9B | 55.54 | $1.42 | N/A |
| ABT | $130.93 | -0.86% | 233.7B | 16.83 | $7.98 | +1.72% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $102.95 | -0.01% | 152.8B | 61.40 | $1.68 | N/A |
| SYK | $374.94 | -0.38% | 144.3B | 50.08 | $7.54 | +0.88% |
| MDT | $89.36 | -2.06% | 119.1B | 25.75 | $3.61 | +3.03% |
| EW | $78.61 | +0.88% | 46B | 32.79 | $2.39 | N/A |
| PHG | $26.20 | -1.54% | 25.5B | 141.32 | $0.19 | +3.29% |
| STE | $221.21 | -6.36% | 23.9B | 37.15 | $6.54 | +0.94% |
| PODD | $277.30 | -8.65% | 21.6B | 93.63 | $3.28 | N/A |
Stock Comparison
DXCM vs ABT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ABT has a market cap of 233.7B. Regarding current trading prices, DXCM is priced at $76.40, while ABT trades at $130.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ABT's P/E ratio is 16.83. In terms of profitability, DXCM's ROE is +0.26%, compared to ABT's ROE of +0.32%. Regarding short-term risk, DXCM is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ABT's competition here
DXCM vs BSX-PA Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DXCM is priced at $76.40, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DXCM's ROE is +0.26%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, DXCM is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BSX-PA's competition here
DXCM vs BSX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BSX has a market cap of 152.8B. Regarding current trading prices, DXCM is priced at $76.40, while BSX trades at $102.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BSX's P/E ratio is 61.40. In terms of profitability, DXCM's ROE is +0.26%, compared to BSX's ROE of +0.12%. Regarding short-term risk, DXCM is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BSX's competition here
DXCM vs SYK Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SYK has a market cap of 144.3B. Regarding current trading prices, DXCM is priced at $76.40, while SYK trades at $374.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SYK's P/E ratio is 50.08. In terms of profitability, DXCM's ROE is +0.26%, compared to SYK's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SYK's competition here
DXCM vs MDT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, MDT has a market cap of 119.1B. Regarding current trading prices, DXCM is priced at $76.40, while MDT trades at $89.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas MDT's P/E ratio is 25.75. In terms of profitability, DXCM's ROE is +0.26%, compared to MDT's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check MDT's competition here
DXCM vs EW Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, EW has a market cap of 46B. Regarding current trading prices, DXCM is priced at $76.40, while EW trades at $78.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas EW's P/E ratio is 32.79. In terms of profitability, DXCM's ROE is +0.26%, compared to EW's ROE of +0.41%. Regarding short-term risk, DXCM is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check EW's competition here
DXCM vs PHG Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, PHG has a market cap of 25.5B. Regarding current trading prices, DXCM is priced at $76.40, while PHG trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas PHG's P/E ratio is 141.32. In terms of profitability, DXCM's ROE is +0.26%, compared to PHG's ROE of +0.01%. Regarding short-term risk, DXCM is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check PHG's competition here
DXCM vs STE Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, STE has a market cap of 23.9B. Regarding current trading prices, DXCM is priced at $76.40, while STE trades at $221.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas STE's P/E ratio is 37.15. In terms of profitability, DXCM's ROE is +0.26%, compared to STE's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check STE's competition here
DXCM vs PODD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, PODD has a market cap of 21.6B. Regarding current trading prices, DXCM is priced at $76.40, while PODD trades at $277.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas PODD's P/E ratio is 93.63. In terms of profitability, DXCM's ROE is +0.26%, compared to PODD's ROE of +0.21%. Regarding short-term risk, DXCM is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check PODD's competition here
DXCM vs ZBH Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ZBH has a market cap of 19.6B. Regarding current trading prices, DXCM is priced at $76.40, while ZBH trades at $91.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ZBH's P/E ratio is 24.20. In terms of profitability, DXCM's ROE is +0.26%, compared to ZBH's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ZBH's competition here
DXCM vs ABMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DXCM is priced at $76.40, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DXCM's ROE is +0.26%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ABMD's competition here
DXCM vs SNN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SNN has a market cap of 15.8B. Regarding current trading prices, DXCM is priced at $76.40, while SNN trades at $35.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SNN's P/E ratio is 32.54. In terms of profitability, DXCM's ROE is +0.26%, compared to SNN's ROE of +0.09%. Regarding short-term risk, DXCM is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SNN's competition here
DXCM vs SWAV Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DXCM is priced at $76.40, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DXCM's ROE is +0.26%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, DXCM is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SWAV's competition here
DXCM vs ALGN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ALGN has a market cap of 10.1B. Regarding current trading prices, DXCM is priced at $76.40, while ALGN trades at $136.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ALGN's P/E ratio is 23.32. In terms of profitability, DXCM's ROE is +0.26%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ALGN's competition here
DXCM vs PEN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, PEN has a market cap of 9.4B. Regarding current trading prices, DXCM is priced at $76.40, while PEN trades at $239.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas PEN's P/E ratio is 63.65. In terms of profitability, DXCM's ROE is +0.26%, compared to PEN's ROE of +0.12%. Regarding short-term risk, DXCM is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check PEN's competition here
DXCM vs GMED Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, GMED has a market cap of 7.9B. Regarding current trading prices, DXCM is priced at $76.40, while GMED trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas GMED's P/E ratio is 43.81. In terms of profitability, DXCM's ROE is +0.26%, compared to GMED's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check GMED's competition here
DXCM vs BIO-B Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BIO-B has a market cap of 7.5B. Regarding current trading prices, DXCM is priced at $76.40, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, DXCM's ROE is +0.26%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BIO-B's competition here
DXCM vs BIO Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BIO has a market cap of 7.1B. Regarding current trading prices, DXCM is priced at $76.40, while BIO trades at $264.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BIO's P/E ratio is 23.80. In terms of profitability, DXCM's ROE is +0.26%, compared to BIO's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BIO's competition here
DXCM vs IRTC Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, IRTC has a market cap of 5.1B. Regarding current trading prices, DXCM is priced at $76.40, while IRTC trades at $156.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas IRTC's P/E ratio is -54.28. In terms of profitability, DXCM's ROE is +0.26%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, DXCM is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check IRTC's competition here
DXCM vs GKOS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, GKOS has a market cap of 4.9B. Regarding current trading prices, DXCM is priced at $76.40, while GKOS trades at $88.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas GKOS's P/E ratio is -52.59. In terms of profitability, DXCM's ROE is +0.26%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, DXCM is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check GKOS's competition here
DXCM vs NARI Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DXCM is priced at $76.40, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas NARI's P/E ratio is -59.24. In terms of profitability, DXCM's ROE is +0.26%, compared to NARI's ROE of -0.18%. Regarding short-term risk, DXCM is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NARI's competition here
DXCM vs BRKR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BRKR has a market cap of 4.6B. Regarding current trading prices, DXCM is priced at $76.40, while BRKR trades at $30.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BRKR's P/E ratio is 57.42. In terms of profitability, DXCM's ROE is +0.26%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, DXCM is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BRKR's competition here
DXCM vs TMDX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, TMDX has a market cap of 3.9B. Regarding current trading prices, DXCM is priced at $76.40, while TMDX trades at $118.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas TMDX's P/E ratio is 57.83. In terms of profitability, DXCM's ROE is +0.26%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, DXCM is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TMDX's competition here
DXCM vs ITGR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ITGR has a market cap of 3.7B. Regarding current trading prices, DXCM is priced at $76.40, while ITGR trades at $105.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ITGR's P/E ratio is 45.53. In terms of profitability, DXCM's ROE is +0.26%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ITGR's competition here
DXCM vs AXNX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DXCM is priced at $76.40, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DXCM's ROE is +0.26%, compared to AXNX's ROE of -0.02%. Regarding short-term risk, DXCM is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check AXNX's competition here
DXCM vs LIVN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, LIVN has a market cap of 2.7B. Regarding current trading prices, DXCM is priced at $76.40, while LIVN trades at $47.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas LIVN's P/E ratio is -12.59. In terms of profitability, DXCM's ROE is +0.26%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, DXCM is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check LIVN's competition here
DXCM vs INSP Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, INSP has a market cap of 2.3B. Regarding current trading prices, DXCM is priced at $76.40, while INSP trades at $78.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas INSP's P/E ratio is 45.49. In terms of profitability, DXCM's ROE is +0.26%, compared to INSP's ROE of +0.08%. Regarding short-term risk, DXCM is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check INSP's competition here
DXCM vs ATEC Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ATEC has a market cap of 2.2B. Regarding current trading prices, DXCM is priced at $76.40, while ATEC trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ATEC's P/E ratio is -13.24. In terms of profitability, DXCM's ROE is +0.26%, compared to ATEC's ROE of -2.52%. Regarding short-term risk, DXCM is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ATEC's competition here
DXCM vs PRCT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, PRCT has a market cap of 2.1B. Regarding current trading prices, DXCM is priced at $76.40, while PRCT trades at $45.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas PRCT's P/E ratio is -26.31. In terms of profitability, DXCM's ROE is +0.26%, compared to PRCT's ROE of -0.24%. Regarding short-term risk, DXCM is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PRCT's competition here
DXCM vs NUVA Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DXCM is priced at $76.40, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DXCM's ROE is +0.26%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NUVA's competition here
DXCM vs AORT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, DXCM is priced at $76.40, while AORT trades at $32.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas AORT's P/E ratio is -80.25. In terms of profitability, DXCM's ROE is +0.26%, compared to AORT's ROE of -0.07%. Regarding short-term risk, DXCM is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AORT's competition here
DXCM vs CNMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, DXCM is priced at $76.40, while CNMD trades at $51.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CNMD's P/E ratio is 15.45. In terms of profitability, DXCM's ROE is +0.26%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CNMD's competition here
DXCM vs UFPT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, UFPT has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $76.40, while UFPT trades at $213.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas UFPT's P/E ratio is 24.68. In terms of profitability, DXCM's ROE is +0.26%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, DXCM is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check UFPT's competition here
DXCM vs SSII Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SSII has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $76.40, while SSII trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SSII's P/E ratio is -112.83. In terms of profitability, DXCM's ROE is +0.26%, compared to SSII's ROE of -1.05%. Regarding short-term risk, DXCM is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SSII's competition here
DXCM vs HSKA Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $76.40, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DXCM's ROE is +0.26%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DXCM is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check HSKA's competition here
DXCM vs AHCO Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, DXCM is priced at $76.40, while AHCO trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas AHCO's P/E ratio is 17.02. In terms of profitability, DXCM's ROE is +0.26%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check AHCO's competition here
DXCM vs SILK Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $76.40, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SILK's P/E ratio is -18.96. In terms of profitability, DXCM's ROE is +0.26%, compared to SILK's ROE of -0.29%. Regarding short-term risk, DXCM is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SILK's competition here
DXCM vs FNA Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $76.40, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas FNA's P/E ratio is -19.83. In terms of profitability, DXCM's ROE is +0.26%, compared to FNA's ROE of -0.36%. Regarding short-term risk, DXCM is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check FNA's competition here
DXCM vs IART Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, IART has a market cap of 1B. Regarding current trading prices, DXCM is priced at $76.40, while IART trades at $12.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas IART's P/E ratio is -1.98. In terms of profitability, DXCM's ROE is +0.26%, compared to IART's ROE of -0.36%. Regarding short-term risk, DXCM is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check IART's competition here
DXCM vs ESTA Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ESTA has a market cap of 1B. Regarding current trading prices, DXCM is priced at $76.40, while ESTA trades at $41.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ESTA's P/E ratio is -11.30. In terms of profitability, DXCM's ROE is +0.26%, compared to ESTA's ROE of -2.41%. Regarding short-term risk, DXCM is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check ESTA's competition here
DXCM vs INMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, INMD has a market cap of 981.5M. Regarding current trading prices, DXCM is priced at $76.40, while INMD trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas INMD's P/E ratio is 5.93. In terms of profitability, DXCM's ROE is +0.26%, compared to INMD's ROE of +0.27%. Regarding short-term risk, DXCM is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check INMD's competition here
DXCM vs IRMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, IRMD has a market cap of 889.5M. Regarding current trading prices, DXCM is priced at $76.40, while IRMD trades at $70.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas IRMD's P/E ratio is 43.43. In terms of profitability, DXCM's ROE is +0.26%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, DXCM is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check IRMD's competition here
DXCM vs CSII Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DXCM is priced at $76.40, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CSII's P/E ratio is -20.83. In terms of profitability, DXCM's ROE is +0.26%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DXCM is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check CSII's competition here
DXCM vs TNDM Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, TNDM has a market cap of 758.8M. Regarding current trading prices, DXCM is priced at $76.40, while TNDM trades at $14.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas TNDM's P/E ratio is -3.65. In terms of profitability, DXCM's ROE is +0.26%, compared to TNDM's ROE of -1.04%. Regarding short-term risk, DXCM is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TNDM's competition here
DXCM vs CRY Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, DXCM is priced at $76.40, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CRY's P/E ratio is 425.71. In terms of profitability, DXCM's ROE is +0.26%, compared to CRY's ROE of -0.07%. Regarding short-term risk, DXCM is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check CRY's competition here
DXCM vs SIBN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SIBN has a market cap of 676.4M. Regarding current trading prices, DXCM is priced at $76.40, while SIBN trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SIBN's P/E ratio is -27.51. In terms of profitability, DXCM's ROE is +0.26%, compared to SIBN's ROE of -0.14%. Regarding short-term risk, DXCM is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SIBN's competition here
DXCM vs AXGN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, AXGN has a market cap of 639.1M. Regarding current trading prices, DXCM is priced at $76.40, while AXGN trades at $13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas AXGN's P/E ratio is -138.90. In terms of profitability, DXCM's ROE is +0.26%, compared to AXGN's ROE of -0.04%. Regarding short-term risk, DXCM is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AXGN's competition here
DXCM vs APEN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DXCM is priced at $76.40, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas APEN's P/E ratio is -9.43. In terms of profitability, DXCM's ROE is +0.26%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DXCM is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check APEN's competition here
DXCM vs SMLR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SMLR has a market cap of 534.9M. Regarding current trading prices, DXCM is priced at $76.40, while SMLR trades at $35.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SMLR's P/E ratio is 7.92. In terms of profitability, DXCM's ROE is +0.26%, compared to SMLR's ROE of +0.17%. Regarding short-term risk, DXCM is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SMLR's competition here
DXCM vs ZIMV Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ZIMV has a market cap of 530.5M. Regarding current trading prices, DXCM is priced at $76.40, while ZIMV trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ZIMV's P/E ratio is -27.26. In terms of profitability, DXCM's ROE is +0.26%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, DXCM is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ZIMV's competition here
DXCM vs CTKB Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CTKB has a market cap of 512.7M. Regarding current trading prices, DXCM is priced at $76.40, while CTKB trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CTKB's P/E ratio is -80.60. In terms of profitability, DXCM's ROE is +0.26%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, DXCM is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CTKB's competition here
DXCM vs SRDX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SRDX has a market cap of 506.3M. Regarding current trading prices, DXCM is priced at $76.40, while SRDX trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SRDX's P/E ratio is -25.29. In terms of profitability, DXCM's ROE is +0.26%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, DXCM is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SRDX's competition here
DXCM vs AVNS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, AVNS has a market cap of 501.6M. Regarding current trading prices, DXCM is priced at $76.40, while AVNS trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas AVNS's P/E ratio is -1.08. In terms of profitability, DXCM's ROE is +0.26%, compared to AVNS's ROE of -0.50%. Regarding short-term risk, DXCM is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AVNS's competition here
DXCM vs OFIX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, OFIX has a market cap of 494.1M. Regarding current trading prices, DXCM is priced at $76.40, while OFIX trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas OFIX's P/E ratio is -3.95. In terms of profitability, DXCM's ROE is +0.26%, compared to OFIX's ROE of -0.25%. Regarding short-term risk, DXCM is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check OFIX's competition here
DXCM vs CBLL Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CBLL has a market cap of 473.3M. Regarding current trading prices, DXCM is priced at $76.40, while CBLL trades at $12.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CBLL's P/E ratio is -3.58. In terms of profitability, DXCM's ROE is +0.26%, compared to CBLL's ROE of -0.48%. Regarding short-term risk, DXCM is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CBLL's competition here
DXCM vs KIDS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, KIDS has a market cap of 468.4M. Regarding current trading prices, DXCM is priced at $76.40, while KIDS trades at $17.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas KIDS's P/E ratio is -10.51. In terms of profitability, DXCM's ROE is +0.26%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, DXCM is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check KIDS's competition here
DXCM vs BVS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BVS has a market cap of 459.2M. Regarding current trading prices, DXCM is priced at $76.40, while BVS trades at $7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BVS's P/E ratio is 230.67. In terms of profitability, DXCM's ROE is +0.26%, compared to BVS's ROE of -0.00%. Regarding short-term risk, DXCM is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BVS's competition here
DXCM vs PACB Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, PACB has a market cap of 405.1M. Regarding current trading prices, DXCM is priced at $76.40, while PACB trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas PACB's P/E ratio is -0.49. In terms of profitability, DXCM's ROE is +0.26%, compared to PACB's ROE of -1.70%. Regarding short-term risk, DXCM is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PACB's competition here
DXCM vs SENS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SENS has a market cap of 393.5M. Regarding current trading prices, DXCM is priced at $76.40, while SENS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SENS's P/E ratio is -4.83. In terms of profitability, DXCM's ROE is +0.26%, compared to SENS's ROE of -2.84%. Regarding short-term risk, DXCM is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SENS's competition here
DXCM vs VREX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, VREX has a market cap of 393.4M. Regarding current trading prices, DXCM is priced at $76.40, while VREX trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas VREX's P/E ratio is -9.20. In terms of profitability, DXCM's ROE is +0.26%, compared to VREX's ROE of -0.08%. Regarding short-term risk, DXCM is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check VREX's competition here
DXCM vs TMCI Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, TMCI has a market cap of 385.6M. Regarding current trading prices, DXCM is priced at $76.40, while TMCI trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas TMCI's P/E ratio is -7.21. In terms of profitability, DXCM's ROE is +0.26%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, DXCM is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TMCI's competition here
DXCM vs SNWV Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SNWV has a market cap of 340.7M. Regarding current trading prices, DXCM is priced at $76.40, while SNWV trades at $35.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SNWV's P/E ratio is -6.38. In terms of profitability, DXCM's ROE is +0.26%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, DXCM is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SNWV's competition here
DXCM vs BFLY Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BFLY has a market cap of 337.3M. Regarding current trading prices, DXCM is priced at $76.40, while BFLY trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BFLY's P/E ratio is -4.79. In terms of profitability, DXCM's ROE is +0.26%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, DXCM is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BFLY's competition here
DXCM vs CLPT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CLPT has a market cap of 305.8M. Regarding current trading prices, DXCM is priced at $76.40, while CLPT trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CLPT's P/E ratio is -14.24. In terms of profitability, DXCM's ROE is +0.26%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, DXCM is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CLPT's competition here
DXCM vs BFLY-WT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BFLY-WT has a market cap of 299.9M. Regarding current trading prices, DXCM is priced at $76.40, while BFLY-WT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.26%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, DXCM is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BFLY-WT's competition here
DXCM vs NNOX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, NNOX has a market cap of 296.5M. Regarding current trading prices, DXCM is priced at $76.40, while NNOX trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas NNOX's P/E ratio is -5.11. In terms of profitability, DXCM's ROE is +0.26%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, DXCM is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check NNOX's competition here
DXCM vs NPCE Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, NPCE has a market cap of 294.5M. Regarding current trading prices, DXCM is priced at $76.40, while NPCE trades at $8.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas NPCE's P/E ratio is -10.95. In terms of profitability, DXCM's ROE is +0.26%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, DXCM is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NPCE's competition here
DXCM vs RXST Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, RXST has a market cap of 292.2M. Regarding current trading prices, DXCM is priced at $76.40, while RXST trades at $7.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas RXST's P/E ratio is -10.89. In terms of profitability, DXCM's ROE is +0.26%, compared to RXST's ROE of -0.10%. Regarding short-term risk, DXCM is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check RXST's competition here
DXCM vs VMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, VMD has a market cap of 275.4M. Regarding current trading prices, DXCM is priced at $76.40, while VMD trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas VMD's P/E ratio is 23.67. In terms of profitability, DXCM's ROE is +0.26%, compared to VMD's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check VMD's competition here
DXCM vs TCMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, TCMD has a market cap of 273.7M. Regarding current trading prices, DXCM is priced at $76.40, while TCMD trades at $12.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas TCMD's P/E ratio is 19.81. In terms of profitability, DXCM's ROE is +0.26%, compared to TCMD's ROE of +0.07%. Regarding short-term risk, DXCM is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TCMD's competition here
DXCM vs CATX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CATX has a market cap of 271.7M. Regarding current trading prices, DXCM is priced at $76.40, while CATX trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CATX's P/E ratio is -2.98. In terms of profitability, DXCM's ROE is +0.26%, compared to CATX's ROE of -0.27%. Regarding short-term risk, DXCM is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CATX's competition here
DXCM vs CERS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CERS has a market cap of 232M. Regarding current trading prices, DXCM is priced at $76.40, while CERS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CERS's P/E ratio is -12.10. In terms of profitability, DXCM's ROE is +0.26%, compared to CERS's ROE of -0.34%. Regarding short-term risk, DXCM is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CERS's competition here
DXCM vs MASS Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, MASS has a market cap of 228.4M. Regarding current trading prices, DXCM is priced at $76.40, while MASS trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas MASS's P/E ratio is -2.68. In terms of profitability, DXCM's ROE is +0.26%, compared to MASS's ROE of -0.13%. Regarding short-term risk, DXCM is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check MASS's competition here
DXCM vs OM Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, OM has a market cap of 226.8M. Regarding current trading prices, DXCM is priced at $76.40, while OM trades at $13.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas OM's P/E ratio is -0.68. In terms of profitability, DXCM's ROE is +0.26%, compared to OM's ROE of -0.98%. Regarding short-term risk, DXCM is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check OM's competition here
DXCM vs NVRO Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DXCM is priced at $76.40, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DXCM's ROE is +0.26%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DXCM is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NVRO's competition here
DXCM vs BWAY Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BWAY has a market cap of 222.2M. Regarding current trading prices, DXCM is priced at $76.40, while BWAY trades at $11.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BWAY's P/E ratio is 53.45. In terms of profitability, DXCM's ROE is +0.26%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, DXCM is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BWAY's competition here
DXCM vs QTRX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, QTRX has a market cap of 221.6M. Regarding current trading prices, DXCM is priced at $76.40, while QTRX trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas QTRX's P/E ratio is -3.83. In terms of profitability, DXCM's ROE is +0.26%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, DXCM is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check QTRX's competition here
DXCM vs SGHT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, SGHT has a market cap of 219.2M. Regarding current trading prices, DXCM is priced at $76.40, while SGHT trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas SGHT's P/E ratio is -4.33. In terms of profitability, DXCM's ROE is +0.26%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, DXCM is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SGHT's competition here
DXCM vs EYES Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, DXCM is priced at $76.40, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas EYES's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.26%, compared to EYES's ROE of -0.26%. Regarding short-term risk, DXCM is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check EYES's competition here
DXCM vs MGRM Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, MGRM has a market cap of 195.3M. Regarding current trading prices, DXCM is priced at $76.40, while MGRM trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas MGRM's P/E ratio is -10.80. In terms of profitability, DXCM's ROE is +0.26%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, DXCM is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check MGRM's competition here
DXCM vs CVRX Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, CVRX has a market cap of 189.3M. Regarding current trading prices, DXCM is priced at $76.40, while CVRX trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas CVRX's P/E ratio is -3.51. In terms of profitability, DXCM's ROE is +0.26%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, DXCM is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CVRX's competition here
DXCM vs INGN Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, INGN has a market cap of 174.2M. Regarding current trading prices, DXCM is priced at $76.40, while INGN trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas INGN's P/E ratio is -5.63. In terms of profitability, DXCM's ROE is +0.26%, compared to INGN's ROE of -0.15%. Regarding short-term risk, DXCM is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check INGN's competition here
DXCM vs PROF Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, PROF has a market cap of 166.5M. Regarding current trading prices, DXCM is priced at $76.40, while PROF trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas PROF's P/E ratio is -4.43. In terms of profitability, DXCM's ROE is +0.26%, compared to PROF's ROE of -0.70%. Regarding short-term risk, DXCM is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PROF's competition here
DXCM vs ELMD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ELMD has a market cap of 156.1M. Regarding current trading prices, DXCM is priced at $76.40, while ELMD trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ELMD's P/E ratio is 23.57. In terms of profitability, DXCM's ROE is +0.26%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, DXCM is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ELMD's competition here
DXCM vs LNSR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, LNSR has a market cap of 153.2M. Regarding current trading prices, DXCM is priced at $76.40, while LNSR trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas LNSR's P/E ratio is -2.65. In terms of profitability, DXCM's ROE is +0.26%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, DXCM is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check LNSR's competition here
DXCM vs OWLT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, OWLT has a market cap of 152.9M. Regarding current trading prices, DXCM is priced at $76.40, while OWLT trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas OWLT's P/E ratio is -5.75. In terms of profitability, DXCM's ROE is +0.26%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, DXCM is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check OWLT's competition here
DXCM vs TLSI Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, TLSI has a market cap of 150M. Regarding current trading prices, DXCM is priced at $76.40, while TLSI trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas TLSI's P/E ratio is -3.59. In terms of profitability, DXCM's ROE is +0.26%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, DXCM is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TLSI's competition here
DXCM vs RPID Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, RPID has a market cap of 149M. Regarding current trading prices, DXCM is priced at $76.40, while RPID trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas RPID's P/E ratio is -3.30. In terms of profitability, DXCM's ROE is +0.26%, compared to RPID's ROE of -0.56%. Regarding short-term risk, DXCM is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check RPID's competition here
DXCM vs MXCT Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, MXCT has a market cap of 147.1M. Regarding current trading prices, DXCM is priced at $76.40, while MXCT trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas MXCT's P/E ratio is -3.29. In terms of profitability, DXCM's ROE is +0.26%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, DXCM is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check MXCT's competition here
DXCM vs AVR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, AVR has a market cap of 135M. Regarding current trading prices, DXCM is priced at $76.40, while AVR trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas AVR's P/E ratio is -1.04. In terms of profitability, DXCM's ROE is +0.26%, compared to AVR's ROE of -2.92%. Regarding short-term risk, DXCM is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AVR's competition here
DXCM vs BSGM Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, BSGM has a market cap of 117.5M. Regarding current trading prices, DXCM is priced at $76.40, while BSGM trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas BSGM's P/E ratio is -7.08. In terms of profitability, DXCM's ROE is +0.26%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, DXCM is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BSGM's competition here
DXCM vs ANIK Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ANIK has a market cap of 116.9M. Regarding current trading prices, DXCM is priced at $76.40, while ANIK trades at $8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ANIK's P/E ratio is -9.01. In terms of profitability, DXCM's ROE is +0.26%, compared to ANIK's ROE of -0.35%. Regarding short-term risk, DXCM is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ANIK's competition here
DXCM vs RCEL Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, RCEL has a market cap of 112.3M. Regarding current trading prices, DXCM is priced at $76.40, while RCEL trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas RCEL's P/E ratio is -1.94. In terms of profitability, DXCM's ROE is +0.26%, compared to RCEL's ROE of -6.33%. Regarding short-term risk, DXCM is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check RCEL's competition here
DXCM vs LUCD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, LUCD has a market cap of 107.8M. Regarding current trading prices, DXCM is priced at $76.40, while LUCD trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas LUCD's P/E ratio is -0.85. In terms of profitability, DXCM's ROE is +0.26%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, DXCM is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check LUCD's competition here
DXCM vs ICAD Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, DXCM is priced at $76.40, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ICAD's P/E ratio is -20.37. In terms of profitability, DXCM's ROE is +0.26%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, DXCM is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ICAD's competition here
DXCM vs NSPR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, NSPR has a market cap of 101M. Regarding current trading prices, DXCM is priced at $76.40, while NSPR trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas NSPR's P/E ratio is -2.99. In terms of profitability, DXCM's ROE is +0.26%, compared to NSPR's ROE of -1.31%. Regarding short-term risk, DXCM is less volatile compared to NSPR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check NSPR's competition here
DXCM vs HJLI Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, DXCM is priced at $76.40, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas HJLI's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.26%, compared to HJLI's ROE of -0.57%. Regarding short-term risk, DXCM is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check HJLI's competition here
DXCM vs FONR Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, FONR has a market cap of 97M. Regarding current trading prices, DXCM is priced at $76.40, while FONR trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas FONR's P/E ratio is 12.51. In terms of profitability, DXCM's ROE is +0.26%, compared to FONR's ROE of +0.07%. Regarding short-term risk, DXCM is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check FONR's competition here
DXCM vs ASXC Comparison August 2025
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 30.9B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, DXCM is priced at $76.40, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 55.54, whereas ASXC's P/E ratio is -1.12. In terms of profitability, DXCM's ROE is +0.26%, compared to ASXC's ROE of -56.86%. Regarding short-term risk, DXCM is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ASXC's competition here